Modality
Peptide
MOA
KRASG12Di
Target
GIP-R
Pathway
Incretin
Gastric Ca
Development Pipeline
Preclinical
~Jul 2015
→ ~Oct 2016
Phase 1
~Jan 2017
→ ~Apr 2018
Phase 2
~Jul 2018
→ ~Oct 2019
Phase 3
Jan 2020
→ May 2030
Phase 3Current
NCT03410658
507 pts·Gastric Ca
2020-01→TBD·Completed
NCT03170952
927 pts·Gastric Ca
2025-10→2030-05·Completed
1,434 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-11-224mo agoOrphan Drug· Gastric Ca
2030-05-114.1y awayPh3 Readout· Gastric Ca
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P3
Complet…
P3
Complet…
Catalysts
Orphan Drug
2025-11-22 · 4mo ago
Gastric Ca
Ph3 Readout
2030-05-11 · 4.1y away
Gastric Ca
Completed|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03410658 | Phase 3 | Gastric Ca | Completed | 507 | OS |
| NCT03170952 | Phase 3 | Gastric Ca | Completed | 927 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| Capifutibatinib | Intra-Cellular | Phase 3 | GIP-R | |
| Terarasimod | Krystal Biotech | Phase 1/2 | PI3Kα |